Wolverine Trading
AVDL

Wolverine Trading’s Avadel Pharmaceuticals AVDL Stock Holding History

Wolverine Trading’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-20,776
Closed -$293K – 4474
2023
Q4 		$293K Buy
20,776
+5,984
+40% +$70.3K ﹤0.01% 3487
2023
Q3 		$152K Sell
14,792
-1,661
-10% -$22.2K ﹤0.01% 3855
2023
Q2 		$244K Buy
+16,453
New +$214K ﹤0.01% 3321
2021
Q2 		– Sell
-10,274
Closed -$81.6K – 5917
2021
Q1 		$91K Sell
10,274
-1,627
-14% -$13.2K ﹤0.01% 5474
2020
Q4 		$80K Buy
+11,901
New +$74.4K ﹤0.01% 4517
2020
Q2 		– Sell
-30,861
Closed -$272K – 4553
2020
Q1 		$269K Buy
+30,861
New +$237K ﹤0.01% 3336
2019
Q4 		– Sell
-10,745
Closed -$46K – 4629
2019
Q3 		$46K Sell
10,745
-14,327
-57% -$35.9K ﹤0.01% 4060
2019
Q2 		$72K Buy
+25,072
New +$43.1K ﹤0.01% 4111
2018
Q1 		– Sell
-13,774
Closed -$121K – 5082
2017
Q4 		$113K Buy
+13,774
New +$129K ﹤0.01% 4413

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Wolverine Trading's AVDL Position: Q1 2024 in Review

Wolverine Trading sold out of Avadel Pharmaceuticals (AVDL) in Q1 2024, closing a stake of 20,776 shares — an estimated $293K sold.

Wolverine Trading first reported a position in AVDL in Q4 2017 and held it in 9 quarters. The position peaked at $293K in Q4 2023. 127 funds tracked by Wall St. Rank hold AVDL as of Q1 2024.

  • Wolverine Trading reported no remaining Avadel Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Wolverine Trading sold 20,776 Avadel Pharmaceuticals shares in Q1 2024, an estimated $293K.
  • Wolverine Trading first reported a position in Avadel Pharmaceuticals in Q4 2017 and held it in 9 quarters.
  • Wolverine Trading's Avadel Pharmaceuticals position peaked at $293K in Q4 2023.
  • 127 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2024.

Based on Wolverine Trading's 13F filing for Q1 2024, filed 15 May 2024.